A5025588597- Diabetes Management and Research
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Diabetes Management and Education
- Diabetes Treatment and Management
- Pancreatic function and diabetes
- Mobile Health and mHealth Applications
- Diabetes and associated disorders
- COVID-19 Clinical Research Studies
- Health and Lifestyle Studies
Western University
2021-2023
Abstract Aims Among adults with insulin‐ and/or secretagogue‐treated diabetes in the United States, very little is known about real‐world descriptive epidemiology of iatrogenic severe (level 3) hypoglycaemia. Addressing this gap, we collected primary, longitudinal data to quantify absolute frequency events as well incidence rates and proportions. Materials Methods iNPHORM a US‐wide, 12‐month ambidirectional panel survey (2020‐2021). Adults type 1 mellitus (T1DM) or 2 (T2DM) were recruited...
Hypoglycemia prognostic models contingent on prospective, self-reported survey data offer a powerful avenue for determining real-world event susceptibility and interventional targets.This protocol describes the design implementation of 1-year iNPHORM (Investigating Novel Predictions Occurrence Using Real-world Models) study, which aims to measure severe nonsevere hypoglycemia incidence (daytime nocturnal) in American adults with type 1 or 2 diabetes mellitus prescribed insulin and/or...
We aimed to develop and internally validate a real-world prognostic model for Level 3 hypoglycaemia risk compatible with outpatient care in the United States.iNPHORM is 12-month, US-based panel survey. Adults (18-90 years old) type 1 diabetes mellitus or insulin- and/or secretagogue-treated 2 were recruited from nationwide, probability-based internet panel. Among participants completing ≥ follow-up questionnaire(s), we modelled 1-year using Andersen Gill's Cox survival penalized regression...
This American study quantifies how and the extent to which glycemic management has suffered due COVID-19, nearly one year after first USA-based case was detected. cross-sectional evaluates a real-world cohort of Americans (≥18 years old) with type 1 or 2 diabetes (T1D, T2D) taking insulin and/or secretagogues (iNPHORM study, January 2021). A sample 772 respondents analyzed (T1D: 18.9%; male: 49.5%; age: 52.1 [SD: 14.5]). Prevalence confirmed COVID-19 9.3% (March 2020 Nearly 25% reported...
<sec> <title>BACKGROUND</title> Hypoglycemia prognostic models contingent on prospective, self-reported survey data offer a powerful avenue for determining real-world event susceptibility and interventional targets. </sec> <title>OBJECTIVE</title> This protocol describes the design implementation of 1-year iNPHORM (Investigating Novel Predictions Occurrence Using Real-world Models) study, which aims to measure severe nonsevere hypoglycemia incidence (daytime nocturnal) in American adults...